News‎ > ‎Full Stories‎ > ‎

April 15 2016:

posted Apr 15, 2016, 12:42 AM by Stephanie Wallbank   [ updated Jun 20, 2016, 5:52 AM by Beck Lockwood ]
Edinburgh Molecular imaging Ltd awarded Innovate UK grant to qualify the role of EMI-137 in colorectal cancer lesion detection

Edinburgh Molecular Imaging Ltd (EM Imaging) have announced that the company has received a SBRI Stratified Medicine Connecting the UK Infrastructure Phase I grant from the UK’s innovation agency, Innovate UK. The SBRI grant aims to accelerate and increase the development and adoption of innovative diagnostic tools in order to offer better targeted treatment to patients within the UK healthcare system. It also aims to demonstrate the benefits of companies working within the UK ‘enabling infrastructure', which is made up of specialist organisations that can help companies understand healthcare needs, and design, evaluate and deliver their products and services into the NHS.

EM Imaging is partnering with the National Institute for Health Research Colorectal Therapies Healthcare Technology Co-operative (NIHR Colorectal Therapies HTC) and the NIHR Diagnostic Evidence Co-operative Leeds (NIHR DEC Leeds), both based at the Leeds Teaching Hospitals NHS Trust to qualify the potential role of the novel optical imaging agent EMI-137 for the improved detection of colorectal (CRC) lesion during colonoscopy.

Phase I of the SBRI project will provide an initial demonstration of the clinical and economic utility of EMI-137, thereby providing key inputs for the design of a potential follow-on Phase II SBRI and future clinical studies to be undertaken by EM imaging.

Ian Wilson, CEO of EMI, commented: “EM Imaging are extremely grateful to Innovate UK for their award to formalise the health economic value of EMI-137. The detection of flat, smaller non-polypoid lesion is problematic, which cannot be detected by conventional imaging. EMI-137 potentially addresses this major unmet medical need, by combining targeted molecular probes and advanced imaging technology to improve polyp detection. The whole EM Imaging team is extremely motivated to complete this product’s development and get it into the hands of physicians in order to benefit patients.”

Professor David Jayne, Professor of Surgery at the University of Leeds and Clinical Director of the NIHR Colorectal Therapies HTC in Leeds said: "We are delighted to be working closely with EM Imaging on an Innovate UK-funded project to evaluate an exciting new technique for detecting early bowel tumours. EM Imaging's novel fluorescent molecular probe can help doctors detect more bowel tumours during colonoscopy. This will allow the tumours to be removed before they get to an advanced stage and therefore improve the outlook for the many patients who suffer from this condition.”